Loading…
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-46M | $-46M | $-39M | -48.9% | - | - |
| 2024 | $0M | $-43M | $-43M | $-31M | -35.8% | - | - |
| 2023 | $0M | $-47M | $-48M | $-28M | -33.5% | - | - |
| 2022 | $0M | $-48M | $-48M | $-24M | -33.7% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 50.99 | 55.74 | 52.80 | 51.37 |
| Operating Income | -50.99 | -55.74 | -52.80 | -51.37 |
| EBITDA | -47.62 | -46.54 | -43 | -46.38 |
| EBIT | -47.62 | -46.54 | -43 | -46.38 |
| Pretax Income | -47.62 | -47.51 | -43 | -46.38 |
| Tax Provision | 0.36 | 0.01 | 0 | 0 |
| Net Income | -47.98 | -47.51 | -43 | -46.38 |
| Net Income Common Stockholders | -47.98 | -47.51 | -43 | -46.38 |
| Total Expenses | 50.99 | 55.74 | 52.80 | 51.37 |
| Interest Expense | 0 | 0.96 | 0 | 0 |
| Interest Income | 0.95 | 6.52 | 7.32 | 4.68 |
| Research And Development | 37.92 | 43.72 | 41.84 | 37.59 |
| Selling General And Administration | 13.07 | 12.05 | 11.04 | 13.82 |
| Normalized EBITDA | -46.72 | -46.50 | -43.19 | -46.05 |
| Normalized Income | -47.26 | -47.47 | -43.19 | -46.05 |
| Basic EPS | -0.62 | -0.60 | -0.52 | -0.54 |
| Diluted EPS | -0.62 | -0.60 | -0.52 | -0.54 |
| Tax Effect Of Unusual Items | -0.19 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0.21 | 0 | 0 | 0 |
| Total Unusual Items | -0.90 | -0.04 | 0.19 | -0.33 |
| Total Unusual Items Excluding Goodwill | -0.90 | -0.04 | 0.19 | -0.33 |
| Net Income From Continuing Operation Net Minority Interest | -47.98 | -47.51 | -43 | -46.38 |
| Net Interest Income | 0.95 | 5.55 | 7.32 | 4.68 |
| Net Income From Continuing And Discontinued Operation | -47.98 | -47.51 | -43 | -46.38 |
| Total Operating Income As Reported | -50.99 | -55.76 | -52.88 | -51.41 |
| Diluted Average Shares | 76.91 | 79.79 | 83.47 | 85.29 |
| Basic Average Shares | 76.91 | 79.79 | 83.47 | 85.29 |
| Diluted NI Availto Com Stockholders | -47.98 | -47.51 | -43 | -46.38 |
| Net Income Including Noncontrolling Interests | -47.98 | -47.51 | -43 | -46.38 |
| Net Income Continuous Operations | -47.98 | -47.51 | -43 | -46.38 |
| Other Income Expense | 2.42 | 2.68 | 2.48 | 0.32 |
| Other Non Operating Income Expenses | 3.32 | 2.72 | 2.29 | 0.65 |
| Gain On Sale Of Security | -0.90 | -0.04 | 0.19 | -0.33 |
| Net Non Operating Interest Income Expense | 0.95 | 5.55 | 7.32 | 4.68 |
| Interest Expense Non Operating | 0 | 0.96 | 0 | 0 |
| Interest Income Non Operating | 0.95 | 6.52 | 7.32 | 4.68 |
| Other Operating Expenses | 0 | -0.03 | -0.07 | -0.04 |
| General And Administrative Expense | 13.07 | 12.05 | 11.04 | 13.82 |
| Other Gand A | 13.07 | 12.05 | 11.04 | 13.82 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Anavex Life Sciences Corp.this co. | AVXL | $302M | - | 2.39 | -48.9% | - |
| CapsoVision, Inc. | CV | $319M | - | 22.61 | -190.9% | -12.32 |
| ClearPoint Neuro, Inc. | CLPT | $310M | - | 10.84 | -91.1% | -14.85 |
| Compass Therapeutics, Inc. | CMPX | $301M | - | 1.51 | -33.8% | -1.40 |
| Greenwich LifeSciences, Inc. | GLSI | $299M |
| - |
| 136.71 |
| -623.1% |
| -15.09 |
| Rezolute, Inc. | RZLT | $299M | - | 2.53 | -45.9% | -1.89 |
| Organogenesis Holdings Inc. | ORGO | $296M | 15.33 | 0.97 | 8.5% | 5.55 |
| Protara Therapeutics, Inc. | TARA | $285M | - | 1.41 | -29.2% | -1.99 |
| LENZ Therapeutics, Inc. | LENZ | $284M | - | 1.00 | -28.9% | 0.09 |
| Peer Median | - | 15.33 | 2.02 | -39.8% | -1.94 | |